Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New weekly shot could shed pounds and soothe aching knees

NCT ID NCT05931367

Symptom relief Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 study tested a weekly injection called retatrutide in 445 people who are overweight or have obesity and also have knee osteoarthritis. The goal was to see if it reduces knee pain and helps with weight loss. Participants received either the drug or a placebo for about 77 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Retatrutide (a weekly injection)
What this could lead to
If it works, this could offer a new treatment that helps with both weight loss and knee pain from osteoarthritis.
What could go wrong
This is a completed phase 3 trial, but results are not yet published. The drug may cause side effects or not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

445 people

The number who actually took part.

Started

Aug 2023

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a body mass index (BMI) ≥27 kilogram/kg/m² at screening. * Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight. * Have index knee pain for \>12 weeks prior to screening, and presence of index knee pain for \>15 days over the previous month. * Have knee X-ray with moderate radiographic changes (Kellgren-Lawrence Grade 2 or 3) per central reading at screening. * Currently meets American College of Rheumatology (ACR) Criteria (clinical and radiological) for OA. Exclusion Criteria: * Have had steroid joint injections within 90 days of screening. * Have had other joint injections and procedures within 6 months of screening. * Have joint disease other than osteoarthritis. * Have a self-reported or documented change in body weight \>5 kg (11 pounds) within 90 days prior to screening. * Have been taking weight loss drugs, including over-the-counter medications, within 90 days prior to screening. * Have a prior or planned surgical treatment for obesity. * Have diabetes mellitus.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder osteoarthritis, knee Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Osteo arthritis knee Overweight

Contacts and locations

Locations

  • ALPHA Recherche Clinique

    Québec, G3K 2P8, Canada

  • Alpha Recherche Clinique

    Québec, G2J 0C4, Canada

  • Arizona Research Center

    Phoenix, Arizona, 85053, United States

  • Artemis Institute for Clinical Research

    San Diego, California, 92103, United States

  • Barwon Health

    Geelong, Victoria, 3220, Australia

  • Bluewater Clinical Research Group Inc.

    Sarnia, Ontario, N7T 4X3, Canada

  • C-health Research

    Calgary, Alberta, T2V 4J2, Canada

  • CDH Research Institute

    Maroochydore, Queensland, 4558, Australia

  • CHUAC-Complejo Hospitalario Universitario A Coruña

    A Coruña, 15006, Spain

  • Canadian Phase Onward

    Toronto, Ontario, M3J 0K2, Canada

  • Centro de Estudios de Investigacion Metabolicos y Cardiovasculares

    Ciudad Madero, Tamaulipas, 89440, Mexico

  • Chase Medical Research, LLC

    Waterbury, Connecticut, 06708, United States

  • Clinical Trials of Texas, Inc.

    San Antonio, Texas, 78229, United States

  • Clinvest Research LLC

    Springfield, Missouri, 65807, United States

  • Clínica García Flores SC

    Monterrey, Nuevo León, 64610, Mexico

  • Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)

    Seville, 41003, Spain

  • Complejo Hospitalario Universitario de Ferrol (CHUF)- Hospital Naval")

    Ferrol, A Coruña, 15405, Spain

  • Consultorio Médico

    Guadalajara, Jalisco, 44210, Mexico

  • Core Research Group

    Brisbane, Queensland, 4064, Australia

  • Eastern Health - General Hospital

    St. John's, Newfoundland and Labrador, A1B 3V6, Canada

  • Elite Clinical Trials

    Blackfoot, Idaho, 83221, United States

  • Emeritus Research

    Botany, New South Wales, 2019, Australia

  • Emeritus Research

    Camberwell, Victoria, 3124, Australia

  • Great Lakes Research Group, Inc.

    Bay City, Michigan, 48706, United States

  • Hospital General Universitario de Valencia

    Valencia, Valenciana, 46014, Spain

  • Hospital Quirón Málaga

    Málaga, Andalusia, 29004, Spain

  • Hospital Universitario Infanta Sofía

    San Sebastián de los Reyes, Madrid, 28702, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, Andalusia, 14004, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Catalonia, 08041, Spain

  • IMED Internal Medicine Clin Trials

    Monterrey, Nuevo León, 64020, Mexico

  • Investigacion y Biomedicina de Chihuahua

    Chihuahua City, 31000, Mexico

  • Kohler and Milstein Research S.A. de C.V.

    Mérida, Yucatán, 97070, Mexico

  • Leicester General Hospital

    Leicester, Leicestershire, LE5 4PW, United Kingdom

  • MedVadis Research Corporation

    Waltham, Massachusetts, 02451, United States

  • Mercy Family Clinic

    Dallas, Texas, 75211, United States

  • North Georgia Clinical Research

    Woodstock, Georgia, 30189, United States

  • Northwest Clinical Research Center

    Bellevue, Washington, 98007, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Panthera Biopartners - North London

    Enfield, London, EN3 4GS, United Kingdom

  • Panthera Biopartners - Sheffield

    Sheffield, S2 5FX, United Kingdom

  • Paratus Clinical Research Canberra

    Bruce, Australian Capital Territory, 2617, Australia

  • Paratus Clinical Research Western Sydney

    Blacktown, New South Wales, 2148, Australia

  • Royal Brisbane and Women's Hospital

    Brisbane, Queensland, 4029, Australia

  • Stouffville Medical Research Institute Inc.

    Stouffville, Ontario, L4A 1H2, Canada

  • Suncoast Research Group

    Miami, Florida, 33135, United States

  • Unidad Médica para la Salud Integral

    San Nicolás de los Garza, Nuevo León, 66465, Mexico

  • Viable Clinical Research

    Bridgewater, Nova Scotia, B4V 3N2, Canada

  • Viable Clinical Research

    Scarborough Village, Ontario, M1P 2T7, Canada

  • Wharton Medical Clinic

    Hamilton, Ontario, L8L 5G8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.